Pfizer-Drug PF-08634404 for hepatocellular carcinoma (C6461013)

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
[C6461013] An Interventional Open-label Phase 1b/2 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
Principal Investigator
Headshot of Michael Aaron Morse
Professor of Medicine
Protocol Number
IRB: PRO00119394
NCT: NCT07227012
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL